Please assess the completion status of the following clinical trial:

Trial Title: Tibolone and Placebo in Adjunct to Antidepressant Medication for Women With Menopausal Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females who are currently physically well and between 45 and 65 years of age~* Current DSM-IV diagnosis of depression disorder~* Able to give informed consent~* Menopausal as determined by standardized classification guidelines for female reproductive aging were proposed at the Stages of Reproductive (STRAW) -Aging Workshop and symptom profile on the STRAW~* First-onset or relapse depression during menopause~* Currently taking either an SSRI or SNRI, or no psychotropic medication at all~* Evidence of a normal mammogram in the preceding 12 months.~Exclusion Criteria:~* Patients with known abnormalities in the hypothalamic-pituitary gonadal axis, thyroid dysfunction, central nervous system tumours, active or past history of a venous thromboembolic event, breast pathology, undiagnosed vaginal bleeding or abnormal Pap smear results in the previous 2 years.~* Patients with any significant unstable medical illness such as epilepsy and diabetes or known active cardiac, renal or liver disease; or the presence of illness causing immobilisation.~* Patients experiencing severe melancholia, neurovegetative symptoms or current suicidality necessitating acute hospitalisation or intensive psychiatric treatment.~* Patients with psychotic symptoms or past history of severe mental illness including schizophrenia.~* Use of any form of estrogen, progestin or androgen as hormonal therapy, or antiandrogen including Tibolone or use of phytoestrogen supplements as powder or tablet~* Pregnancy / Lactation~* Smoking cigarettes or other nicotine products~* Illicit drug use~* More than 3 standard drinks per day

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Tibolone (Type: ACTIVE_COMPARATOR): Subjects will take 2.5mg of oral Tibolone daily for the duration of the 12 week trial either alone or in adjunct to currently prescribed anti-depressant medication.
- Placebo (Type: NO_INTERVENTION): Subjects will take oral placebo tablets packaged daily for the duration of the 12 week trial either alone or in adjunct to currently prescribed antidepressant medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).